BCIQ Profiles

Company Profile ReportTarget Profile Report

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

Bolt’s innate immune-activating take on ADCs could bring durable antitumor activity to more patients

Bolt’s $93.5 million series C round will enable the Stanford spinout to clinically test whether its myeloid-activating antibody conjugate can provide durable treatment to a broad swath of HER2-positive solid tumor patients.

Led by Sofinnova Investments, the round also included new investors RA Capital Management, Surveyor Capital, Rock Springs Capital, Samsara BioCapital and Pfizer Ventures, along with existing investors including Novo Holdings, Vivo Capital, Pivotal bioVenture Partners.

Bolt Biotherapeutics Inc.’s immune-stimulating antibody conjugate (ISAC) platform is

Read the full 751 word article

How to gain access

Continue reading with a
two-week free trial.